Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
DIPHENHYDRAMINE HYDROCHLORIDE vs EFIDAC 24 CHLORPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Chlorpheniramine maleate is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated allergic reactions. It also has anticholinergic and sedative properties due to central H1 receptor blockade.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
4 mg orally every 4-6 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Terminal elimination half-life ranges from 14 to 25 hours (mean 20 hours) in adults; prolonged in hepatic or renal impairment (up to 50-60 hours in cirrhosis).
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted via feces (biliary).
Category A/B
Category C
Antihistamine
Antihistamine